Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2016

View Archived Issues

Laboratorios del Dr. Esteve reports sigma1 and mu-opioid receptor ligands

Biorhythm patents L. plantarum strain to treat allergy

Igenica Biotherapeutics presents antineoplastic compounds

Aquinnah Pharmaceuticals reports TAR DNA-binding protein inhibitors

Prana Biotechnology divulges compounds for neurological disorders

Phase I results for new generation fluoroquinolone lascufloxacin

Arsanis MAbs target the LPS-O antigen of Klebsiella pneumoniae ST258

FDA approves Humira for intermediate, posterior and panuveitis

Positive opinion handed down for Belkyra through European decentralized procedure

European and Japanese approvals for Kyprolis in multiple myeloma

Lilly's ixekizumab approved in Japan

New aminomethylcycline shows efficacy in pneumonia murine models

BIND Therapeutics files motion for court approval of Pfizer stalking horse asset purchase agreement

Argenx reports promising initial results from multiple-ascending-dose phase I study of ARGX-113

Takeda files for Japanese approval of ixazomib for relapsed or refractory multiple myeloma

Vimpat approved in Japan as adjunctive therapy to treat partial onset seizures

Phase I results support further development of RE-024 for the potential treatment of PKAN

Soricimed Biopharma's SOR-C13 receives FDA orphan drug designation

Japan first to approve Lumicef worldwide

Evofosfamide in combination with sorafenib shows preliminary efficacy for HCC

PhaseBio initiates phase IIa trial of PB-1046 in heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...